GLP-1
A new class of obesity treatment is on the horizon. CagriSema, the combination of cagrilintide and semaglutide developed by Novo Nordisk, has generated enormous interest after delivering over 20% average weight loss in Phase 3 clinical trials. What Is CagriSema? CagriSema is a fixed-dose, once-weekly subcutaneous injection combining two active
GLP-1
Tirzepatide (Mounjaro/Zepbound) is the most effective weight loss medication ever approved. This complete guide covers mechanism of action, SURMOUNT trial results, dosing, side effects, and how it compares to semaglutide.
GLP-1
Semaglutide has transformed the treatment of type 2 diabetes and obesity. Marketed as Ozempic for diabetes management and Wegovy for chronic weight management, this once-weekly injectable GLP-1 receptor agonist has become one of the most prescribed medications in the United States — and for good reason. Clinical trials show average body
GLP-1
Orforglipron (Foundayo) is the first true oral GLP-1 receptor agonist — FDA approved in April 2026. Here's the complete guide to how it works, clinical results, and who it's for.
GLP-1
A new class of obesity treatment is emerging — and it's more powerful than anything that came before it. Retatrutide (LY3437943), developed by Eli Lilly, is a first-in-class triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 3 data shows average weight loss of up to 28.
GLP-1
Semaglutide and tirzepatide have transformed obesity medicine. The average person on tirzepatide loses 20–22% of their body weight; on semaglutide, 15–17%. Those are numbers that previously required bariatric surgery. But there's a complication the prescribing literature doesn't emphasize enough: a meaningful portion of that
GLP-1
Tirzepatide is a dual GIP/GLP-1 receptor agonist that outperforms semaglutide in head-to-head trials. This complete guide covers mechanism, dosing, side effects, and the SURMOUNT-5 results.
GLP-1
Semaglutide has become one of the most talked-about medications in modern medicine — and for good reason. Sold under brand names like Ozempic, Wegovy, and Rybelsus, this once-weekly injectable (and now oral) drug has demonstrated unprecedented weight loss results, cardiovascular benefits, and a growing list of potential therapeutic applications. Whether you&
GLP-1
Retatrutide (LY3437943) is a triple GLP-1/GIP/glucagon receptor agonist showing 28.7% weight loss in Phase 3 — rivaling bariatric surgery. Here is everything you need to know.
GLP-1
Tirzepatide has quickly become one of the most discussed medications in metabolic medicine. Sold under the brand names Mounjaro (for type 2 diabetes) and Zepbound (for obesity), it represents a new class of treatment: the dual GIP/GLP-1 receptor agonist. Unlike earlier GLP-1 drugs like semaglutide, tirzepatide activates two distinct
GLP-1
If you've been diagnosed with PCOS and struggle with weight, irregular periods, or stubborn insulin resistance, you've probably heard about Ozempic — and wondered whether it might help. The answer, based on growing clinical evidence, is a cautious but increasingly confident: yes. Semaglutide, the GLP-1 receptor agonist
GLP-1
Orforglipron (Foundayo) is the first oral small-molecule GLP-1 receptor agonist approved for weight loss — no injections, no food restrictions, no timing windows. Here's everything you need to know.